When they unblind the data it will be way past the time all the treatment cycles have been completed and the ORR computed. This can not affect the statistics of the median PFS and OS when they are later reached. It could if the patients who did not get Bavi, but who got placebo with their chemo, were allowed to cross over and get Bavi, assuming it works better, but this trial does not allow for that.